At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IPSC Century Therapeutics, Inc.
Trading 10-30 15:32:58 EDT
1.48
+0.02
+1.03%
High1.49Low1.37Vol654.66K
Open1.46D1 Closing1.46Amplitude8.22%
Mkt Cap266.98MTradable Cap148.98MTotal Shares181.00M
T/O938.87KT/O Rate0.65%Tradable Shares101.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Century Therapeutics to Attend Jefferies Global Healthcare Conference
Reuters  ·  10-14
Century Therapeutics to Attend Jefferies Global Healthcare Conference
Century Therapeutics: Cnty-813 Ind Submission Remains on Track for Q4 2026; Initial Clinical Data Anticipated in Second Half of 2027 - SEC Filing
THOMSON REUTERS  ·  10-02
Century Therapeutics: Cnty-813 Ind Submission Remains on Track for Q4 2026; Initial Clinical Data Anticipated in Second Half of 2027 - SEC Filing
Century Therapeutics announces presentation of nonclinical data for CNTY-813
TIPRANKS  ·  10-02
Century Therapeutics announces presentation of nonclinical data for CNTY-813
Century Therapeutics Targets CNTY-813 IND Filing in Q4 2026, Sees Initial Trial Data in 2H 2027
Reuters  ·  10-02
Century Therapeutics Targets CNTY-813 IND Filing in Q4 2026, Sees Initial Trial Data in 2H 2027
Century Therapeutics Director Joseph Truitt Files Initial Beneficial Ownership Statement
Reuters  ·  09-11
Century Therapeutics Director Joseph Truitt Files Initial Beneficial Ownership Statement
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline
TIPRANKS  ·  09-10
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline
Century Therapeutics - Increases Board Size to Seven Directors, Appoints Joseph Truitt Effective Sept 9, 2026 - SEC Filing
THOMSON REUTERS  ·  09-10
Century Therapeutics - Increases Board Size to Seven Directors, Appoints Joseph Truitt Effective Sept 9, 2026 - SEC Filing
Century Therapeutics Appoints Joseph Truitt to Board of Directors
THOMSON REUTERS  ·  09-10
Century Therapeutics Appoints Joseph Truitt to Board of Directors
Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities
TIPRANKS  ·  08-18
Century Therapeutics (IPSC) Gets a Buy from Mizuho Securities
Phil Nadeau Initiates Buy on Century Therapeutics, Citing Promising T1D Program, Advancing Pipeline, and Strong Cash Runway
TIPRANKS  ·  08-13
Phil Nadeau Initiates Buy on Century Therapeutics, Citing Promising T1D Program, Advancing Pipeline, and Strong Cash Runway
Century Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-13
Century Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
Reuters  ·  08-13
MiNK Therapeutics Q2 Loss Narrows on Expense Discipline
Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations
Reuters  ·  08-13
Abeona Therapeutics Q2 Net Loss Widens, Misses Analyst Expectations
Clear Street Sticks to Its Buy Rating for Century Therapeutics (IPSC)
TIPRANKS  ·  08-13
Clear Street Sticks to Its Buy Rating for Century Therapeutics (IPSC)
Century Therapeutics Reports Q2 Results, Pipeline Advancements
TIPRANKS  ·  08-12
Century Therapeutics Reports Q2 Results, Pipeline Advancements
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Reuters  ·  08-12
Century Therapeutics Q2 Net Loss Misses Estimates on Lease Termination Loss
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate
Benzinga Earnings  ·  08-12
Century Therapeutics Q2 EPS $(0.17) Misses $(0.14) Estimate
Century Therapeutics Q2 Net Income USD -34.55 Million Vs. IBES Estimate USD -22.4 Million
Reuters  ·  08-12
Century Therapeutics Q2 Net Income USD -34.55 Million Vs. IBES Estimate USD -22.4 Million
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
THOMSON REUTERS  ·  08-12
Century Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates
Century Therapeutics Q2 Operating Expenses USD 36.527 Million
THOMSON REUTERS  ·  08-12
Century Therapeutics Q2 Operating Expenses USD 36.527 Million

Introduction

Company Name.
Century Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma. The company is also involved in the development of CNTY-102, a bi-specific CD19 + CD22 CAR-iT product candidate for relapsed, refractory B-cell lymphoma and other B-cell malignancies; and CNTY-107, a Nectin-4 CAR-iT targeted product candidate for Nectin-4 positive solid tumors. In addition, it has a strategic collaboration with Bristol-Myers Squibb Company to develop and commercialize up to four iNK or iT programs, including CNTY-104, a multi-specific collaboration program targeting acute myeloid leukemia; and CNTY-106, a multi-specific collaboration program for multiple myeloma. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--